Follow The Filings

DMRA Damora Therapeutics

Damora Therapeutics earnings company data as of 5:02 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by DMRA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DMRA insider trades
  • $253K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Jennifer Jarrett CEO
    Buy
    $253K 12,500 shares at $20.23 +2.5% to stake
    Traded Sep 25 Filed Sep 28
    ↗

Also filed in the last 12 months, not counted as buying or selling: 7 option exercises, 4 sales to cover taxes, and 3 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,3.03,5.03,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 4.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,5.03,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 5.02,5.03,8.01,9.01 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.